Clinical Trial Update: Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for venetoclax combined with IM2 in relapsed/refractory T lymphoblastic lymphoma/leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Disease
• Leukemia
• Lymphoma
• T-lymphoblastic Leukemia
• T-lymphoblastic Lymphoma

Drugs mentioned

• IM2 regimen
• Venetoclax (venetoclax)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Status: UNKNOWN